These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 21191717)

  • 1. Intravitreal bevacizumab for age-related macular degeneration with good visual acuity.
    Takahashi M; Sato T; Kishi S
    Jpn J Ophthalmol; 2010 Nov; 54(6):565-70. PubMed ID: 21191717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravitreal injection of triamcinolone combined with bevacizumab for choroidal neovascularization associated with large retinal pigment epithelial detachment in age-related macular degeneration.
    el Matri L; Chebil A; Kort F; Bouraoui R; Baklouti K; Mghaieth F
    Graefes Arch Clin Exp Ophthalmol; 2010 Jun; 248(6):779-84. PubMed ID: 20169357
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Intravitreal bevacizumab for exudative age-related macular degeneration after multiple treatments.
    Aggio FB; Farah ME; Silva WC; Melo GB
    Graefes Arch Clin Exp Ophthalmol; 2007 Feb; 245(2):215-20. PubMed ID: 17139490
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Same-day triple therapy with photodynamic therapy, intravitreal dexamethasone, and bevacizumab in wet age-related macular degeneration.
    Bakri SJ; Couch SM; McCannel CA; Edwards AO
    Retina; 2009 May; 29(5):573-8. PubMed ID: 19430278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination therapy in exudative age-related macular degeneration: visual outcomes following combined treatment with photodynamic therapy and intravitreal bevacizumab.
    Wan MJ; Hooper PL; Sheidow TG
    Can J Ophthalmol; 2010 Aug; 45(4):375-80. PubMed ID: 20648087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study.
    Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P;
    Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up.
    Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA;
    Retina; 2008; 28(10):1387-94. PubMed ID: 18827735
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intravitreal bevacizumab combined with intravitreal triamcinolone for therapy-resistant exudative age-related macular degeneration.
    Tao Y; Jonas JB
    J Ocul Pharmacol Ther; 2010 Apr; 26(2):207-12. PubMed ID: 20415625
    [TBL] [Abstract][Full Text] [Related]  

  • 9. One-year outcomes of less frequent bevacizumab in age-related macular degeneration.
    Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS
    Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Intravitreal triamcinolone, bevacizumab and pegaptanib for occult choroidal neovascularization.
    Forte R; Cennamo G; Finelli M; Cesarano I; D'Amico G; De Crecchio G; Cennamo G
    Acta Ophthalmol; 2010 Dec; 88(8):e305-10. PubMed ID: 20946332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravitreal injection of bevacizumab combined with verteporfin photodynamic therapy for choroidal neovascularization in age-related macular degeneration.
    Smith BT; Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA
    Retina; 2008 May; 28(5):675-81. PubMed ID: 18463509
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration.
    Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A
    Retina; 2007; 27(4):432-8. PubMed ID: 17420694
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy.
    Wakabayashi T; Gomi F; Sawa M; Tsujikawa M; Nishida K
    Br J Ophthalmol; 2012 Mar; 96(3):394-9. PubMed ID: 21719568
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study.
    Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F
    Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration.
    Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S
    Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fundus autofluorescence not predictive of treatment response to intravitreal bevacizumab in exudative age-related macular degeneration.
    Chhablani J; Kozak IR; Mojana F; Cheng L; Morrison VL; Wang H; Kim JS; Dustin L; Azen S; Freeman WR
    Retina; 2012 Sep; 32(8):1465-70. PubMed ID: 22466489
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pilot study of safety and effect of combined intravitreal bevacizumab and methotrexate for neovascular age-related macular degeneration.
    Soheilian M; Movaseghi M; Ramezani A; Peyman GA
    Eur J Ophthalmol; 2011; 21(1):77-82. PubMed ID: 20872362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration.
    Dhalla MS; Shah GK; Blinder KJ; Ryan EH; Mittra RA; Tewari A
    Retina; 2006; 26(9):988-93. PubMed ID: 17151484
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of intravitreal bevacizumab after unresponsive treatment with intravitreal ranibizumab.
    Almony A; Mansouri A; Shah GK; Blinder KJ
    Can J Ophthalmol; 2011 Apr; 46(2):182-5. PubMed ID: 21708088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predictors of response after intravitreal bevacizumab injection for neovascular age-related macular degeneration.
    Byun YJ; Lee SJ; Koh HJ
    Jpn J Ophthalmol; 2010 Nov; 54(6):571-7. PubMed ID: 21191718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.